Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma.
Jean-Baptiste BachetHélène BlonsPascal HammelIman El HariryFabienne PortalesLaurent MineurJean-Philippe MetgesClaire MulotCamille BourreauJason CainJérôme CrosPierre Laurent-PuigPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
We confirm from a prospective randomized trial that: (i) the presence of ctDNA at baseline is a major prognostic factor, (ii) the early change of ctDNA correlates with treatment outcome, and (iii) the ctDNA could be a predictive biomarker of eryaspase efficacy.